Cancer Drug Resistance
All Journals
Search
Log In
Editor-in-Chief:
Godefridus J. Peters
Indexing:
ESCI
,
PMC
,
Scopus
,
CAS
,
CNKI
,
Dimensions
,
Lens
,
Embase
,
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Journal Flyer
Hot Keywords
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Junior Editorial Board
News
Journal History
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Articles with Video Abstracts
Video Abstract Guidelines
Articles Ebooks
Special Issues
All Special Issues
Ongoing Special Issues
Special Issue Ebooks
Special Issue Guidelines
Special Collections
Volumes
Pre-onlines
Features
Webinars
Academic Talks
Interviews
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Cancer Drug Resistance
Search
Submit
Editor-in-Chief:
Godefridus J. Peters
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Home
Volumes
Volume2
Volume2, Issue2 (2019)
Volume
Drug resistance and combating drug resistance in cancer
Emerging targets in cancer drug resistance
Mechanism of resistance to immune checkpoint inhibitors
Molecular mechanisms of enzalutamide resistance in prostate cancer
New insights into acquired endocrine resistance of breast cancer
Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
Pharmacogenetic and pharmacogenomic discovery strategies
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
Pharmacogenetics of thiopurines
Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities
The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors
Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation
Perspective: plasticity, the enemy of the good
Glutaminase inhibition in renal cell carcinoma therapy
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
Actions for 0 selected articles
Download PDFs >
Cancer Drug Resistance
ISSN 2578-532X (Online)
[email protected]
Navigation
Contact Us
Sitemap
Follow Us
LinkedIn
Twitter
WeChat
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/